Delivery Order SPE2DB24D1205-SPE2DB25FDALC
Award Date 9/12/25
Potential Completion Date 9/15/25
Potential Value $7.7K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of HEPLISAV-B 20 mcg/0.5 mL syringes valued at $2,106.20. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of June 27, 2025. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on October 31, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes valued at $1,684.96, with completion scheduled for November 3, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement under an existing contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,948.68 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 mL syringes on September 8, 2025, with completion scheduled for September 9, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a procurement of hepatitis B vaccine supplies to support federal medical requirements. The order is being fulfilled from AmerisourceBergen's place of performance in...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML vaccine syringes with a firm fixed price ceiling value of $5,476.12 and an ultimate completion date of August 25, 2025. This is a non-set-aside, competitively awarded delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of HEPLISAV-B 20 mcg/0.5 mL syringes valued at $8,424.80 with a firm fixed price structure. The contract, which is not set-aside and was competitively awarded, carries an ultimate completion date of September 8, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,684.96 to supply HEPLISAV-B 20 mcg/0.5 mL syringes on May 27, 2025. The order is a firm fixed price delivery order with an ultimate completion date of May 28, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award does not utilize a set-aside designation and was competitively awarded. This delivery order is a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B hepatitis B vaccine (20 mcg/0.5 ml syringe) with a ceiling value of $2,527.44. The order, issued on May 13, 2025, represents a firm fixed price delivery order without a set-aside designation and is scheduled for ultimate completion by May 14, 2025. AmerisourceBergen will perform this work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $38,637.55 to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes with an ultimate completion date of September 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine approved for use in adults,...
- The Defense Logistics Agency (DLA) awarded a $273,806 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 9, 2025, with completion expected by September 10, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes valued at $3,228.20 with a completion date of August 29, 2025. This delivery order represents a firm fixed-price, competitively awarded contract with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This order falls under the company's larger Indefinite Delivery...